Iain C Macdougall1, William E Strauss, Justin McLaughlin, Zhu Li, Frank Dellanna, Joachim Hertel. 1. Department of Renal Medicine, King's College Hospital, London, United Kingdom;, †AMAG Pharmaceuticals, Inc., Lexington, Massachusetts;, ‡Nephrology Center Karlstr, Dusseldorf, Germany, §Greenville Kidney Care, LLC, Greenville, South Carolina.
Abstract
BACKGROUND AND OBJECTIVES: Few randomized controlled trials have compared intravenous iron products head to head in CKD patients with iron deficiency anemia. This study compared the efficacy and safety of two intravenous iron products (ferumoxytol [Feraheme injection] and iron sucrose [Venofer]) in patients with CKD and iron deficiency anemia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this phase II, randomized, open-label, active-controlled, multicenter clinical trial, patients were randomized 1:1 to either 1.02 g ferumoxytol (2 × 510-mg injections) or 1.0 g iron sucrose administered as either a slow injection or infusion (10 doses for dialysis patients and 5 doses for nondialysis patients). Inclusion criteria included hemoglobin<11.0 g/dl, transferrin saturation<30%, and eGFR<60 ml/min per 1.73 m(2) or a diagnosis of underlying CKD (e.g., nephropathy or nephritis). The primary end point was change in hemoglobin from baseline to week 5. RESULTS: In total, 162 patients were randomized. Demographics were balanced between the treatment groups. Adverse event profiles of the two regimens were fairly similar: overall adverse events, 48% ferumoxytol versus 65% iron sucrose; related adverse events, 10% ferumoxytol versus 16% iron sucrose; and adverse events leading to study discontinuation, 1% ferumoxytol versus 5% iron sucrose. Rates of serious adverse events and related serious adverse events were similar between the ferumoxytol and iron sucrose groups: serious adverse events, 9% versus 7%, respectively and related serious adverse events, 1% versus 1%, respectively. Overall, increases in hemoglobin were similar between treatment groups. Based on an ANOVA model adjusted for baseline hemoglobin level and dialysis status, the least squares mean change from baseline to week 5 was 0.8 ± 0.1 g/dl in the ferumoxytol-treated group and 0.7 ± 0.1 g/dl in the iron sucrose group. The difference in the mean change from baseline between the two treatment groups was 0.1 g/dl (95% confidence interval, -0.2 to 0.4). CONCLUSION: In this randomized, controlled trial, ferumoxytol and iron sucrose showed comparable efficacy and adverse events rates.
RCT Entities:
BACKGROUND AND OBJECTIVES: Few randomized controlled trials have compared intravenous iron products head to head in CKDpatients with iron deficiency anemia. This study compared the efficacy and safety of two intravenous iron products (ferumoxytol [Feraheme injection] and iron sucrose [Venofer]) in patients with CKD and iron deficiency anemia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this phase II, randomized, open-label, active-controlled, multicenter clinical trial, patients were randomized 1:1 to either 1.02 g ferumoxytol (2 × 510-mg injections) or 1.0 g iron sucrose administered as either a slow injection or infusion (10 doses for dialysis patients and 5 doses for nondialysis patients). Inclusion criteria included hemoglobin<11.0 g/dl, transferrin saturation<30%, and eGFR<60 ml/min per 1.73 m(2) or a diagnosis of underlying CKD (e.g., nephropathy or nephritis). The primary end point was change in hemoglobin from baseline to week 5. RESULTS: In total, 162 patients were randomized. Demographics were balanced between the treatment groups. Adverse event profiles of the two regimens were fairly similar: overall adverse events, 48% ferumoxytol versus 65% iron sucrose; related adverse events, 10% ferumoxytol versus 16% iron sucrose; and adverse events leading to study discontinuation, 1% ferumoxytol versus 5% iron sucrose. Rates of serious adverse events and related serious adverse events were similar between the ferumoxytol and iron sucrose groups: serious adverse events, 9% versus 7%, respectively and related serious adverse events, 1% versus 1%, respectively. Overall, increases in hemoglobin were similar between treatment groups. Based on an ANOVA model adjusted for baseline hemoglobin level and dialysis status, the least squares mean change from baseline to week 5 was 0.8 ± 0.1 g/dl in the ferumoxytol-treated group and 0.7 ± 0.1 g/dl in the iron sucrose group. The difference in the mean change from baseline between the two treatment groups was 0.1 g/dl (95% confidence interval, -0.2 to 0.4). CONCLUSION: In this randomized, controlled trial, ferumoxytol and iron sucrose showed comparable efficacy and adverse events rates.
Authors: Robert Provenzano; Brigitte Schiller; Madhumathi Rao; Daniel Coyne; Louis Brenner; Brian J G Pereira Journal: Clin J Am Soc Nephrol Date: 2009-01-28 Impact factor: 8.237
Authors: Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira Journal: J Am Soc Nephrol Date: 2008-06-04 Impact factor: 10.121
Authors: Medha Airy; Sreedhar Mandayam; Aya A Mitani; Tara I Chang; Victoria Y Ding; M Alan Brookhart; Benjamin A Goldstein; Wolfgang C Winkelmayer Journal: Nephrol Dial Transplant Date: 2015-08-26 Impact factor: 5.992
Authors: Michael Auerbach; John Adamson; Andreas Bircher; Christian Breymann; Steven Fishbane; Anat Gafter-Gvili; Christoph Gasche; Jeffrey Gilreath; Giuliano Grazzini; David Henry; Giancarlo Liumbruno; Francesco Locatelli; Iain Macdougall; Manuel Munoz; David Rampton; George Rodgers; Aryeh Shander Journal: Haematologica Date: 2015-05 Impact factor: 9.941
Authors: David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane Journal: J Am Soc Nephrol Date: 2014-12-26 Impact factor: 10.121
Authors: C G Varallyay; G B Toth; R Fu; J P Netto; J Firkins; P Ambady; E A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2017-05-11 Impact factor: 3.825
Authors: Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir Journal: Magn Reson Med Date: 2016-02-18 Impact factor: 4.668
Authors: Dante A Suffredini; Wanying Xu; Junfeng Sun; Jesús Barea-Mendoza; Steven B Solomon; Samuel L Brashears; Andreas Perlegas; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson; Irene Cortés-Puch Journal: Transfusion Date: 2017-06-27 Impact factor: 3.157
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612